Uniqure (NASDAQ:QURE) Upgraded at BidaskClub

BidaskClub upgraded shares of Uniqure (NASDAQ:QURE) from a hold rating to a buy rating in a report released on Thursday morning, BidAskClub reports.

A number of other research analysts also recently commented on the stock. Sanford C. Bernstein initiated coverage on shares of Uniqure in a report on Tuesday, September 24th. They issued an outperform rating and a $73.00 price target for the company. Credit Suisse Group initiated coverage on shares of Uniqure in a report on Tuesday, November 5th. They issued an outperform rating and a $76.00 price target for the company. Stifel Nicolaus initiated coverage on shares of Uniqure in a report on Friday, October 11th. They issued a buy rating and a $79.00 price target for the company. HC Wainwright reaffirmed a buy rating and issued a $73.00 price target on shares of Uniqure in a report on Monday, October 14th. Finally, Mizuho initiated coverage on shares of Uniqure in a report on Thursday, September 12th. They issued a buy rating and a $67.00 price target for the company. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $74.43.

QURE opened at $55.66 on Thursday. The firm has a 50-day simple moving average of $49.56 and a two-hundred day simple moving average of $57.69. Uniqure has a 52 week low of $24.07 and a 52 week high of $82.49. The company has a market capitalization of $2.44 billion, a PE ratio of -23.79 and a beta of 0.84. The company has a quick ratio of 14.33, a current ratio of 14.33 and a debt-to-equity ratio of 0.19.

Uniqure (NASDAQ:QURE) last announced its quarterly earnings results on Monday, October 28th. The biotechnology company reported ($0.58) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.23. Uniqure had a negative net margin of 1,670.86% and a negative return on equity of 51.12%. The firm had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.24 million. As a group, sell-side analysts expect that Uniqure will post -2.98 earnings per share for the current year.

In related news, VP Alexander Edward Kuta III sold 4,000 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $47.26, for a total value of $189,040.00. Following the sale, the vice president now directly owns 30,578 shares of the company’s stock, valued at approximately $1,445,116.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 8,000 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $47.31, for a total transaction of $378,480.00. The disclosure for this sale can be found here. Insiders sold a total of 40,769 shares of company stock worth $1,945,826 over the last three months. 2.91% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the stock. Griffin Asset Management Inc. purchased a new stake in Uniqure in the 2nd quarter worth about $39,000. US Bancorp DE raised its position in Uniqure by 275.5% in the 2nd quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 427 shares during the period. Rockefeller Capital Management L.P. purchased a new stake in Uniqure in the 2nd quarter worth about $78,000. Botty Investors LLC purchased a new stake in Uniqure in the 2nd quarter worth about $78,000. Finally, Aperio Group LLC purchased a new position in shares of Uniqure during the second quarter worth approximately $83,000. 72.56% of the stock is currently owned by institutional investors.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Featured Article: How is the Producer Price Index calculated?

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.